Charles Schwab Investment Management Inc Spero Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

$515 Billion
Q3 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Spero Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 28,565 shares of SPRO stock, worth $33,135. This represents 0.0% of its overall portfolio holdings.

Number of Shares

28,565

Previous 28,565 -0.0%

Holding current value

$33,135

Previous $37,000 2.7%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$1.55 - $2.12 $44,275 - $60,557	28,565 New	28,565 $49,000
Q2 2022 Aug 15, 2022	SELL	$0.74 - $7.44 $48,504 - $487,669	-65,547 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$13.09 - $18.77 $25,669 - $36,807	1,961 Added 3.08%	65,547 $1.05 Million
Q3 2021 Nov 16, 2021	BUY	$13.03 - $19.51 $40,262 - $60,285	3,090 Added 5.11%	63,586 $1.17 Million
Q2 2021 Aug 16, 2021	BUY	$12.22 - $15.79 $87,226 - $112,709	7,138 Added 13.38%	60,496 $845,000
Q1 2021 May 17, 2021	BUY	$13.23 - $21.48 $20,202 - $32,799	1,527 Added 2.95%	53,358 $786,000
Q4 2020 Feb 16, 2021	BUY	$11.65 - $22.07 $190,792 - $361,440	16,377 Added 46.19%	51,831 $1.01 Million
Q2 2020 Aug 14, 2020	BUY	$7.27 - $14.18 $29,734 - $57,996	4,090 Added 13.04%	35,454 $480,000
Q1 2020 May 15, 2020	BUY	$5.27 - $10.41 $21,807 - $43,076	4,138 Added 15.2%	31,364 $254,000
Q3 2019 Nov 08, 2019	BUY	$9.01 - $12.55 $18,993 - $26,455	2,108 Added 8.39%	27,226 $289,000
Q2 2019 Aug 09, 2019	BUY	$10.25 - $14.36 $60,423 - $84,652	5,895 Added 30.67%	25,118 $290,000
Q1 2019 May 14, 2019	BUY	$6.26 - $13.31 $29,396 - $62,503	4,696 Added 32.33%	19,223 $247,000
Q3 2018 Nov 13, 2018	BUY	$9.69 - $17.79 $140,766 - $258,435	14,527 New	14,527 $153,000

Others Institutions Holding SPRO

# of Institutions

Shares Held

13.9M

Call Options Held

200

Put Options Held

200

View Full List

About Spero Therapeutics, Inc.

Ticker SPRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,067,500
Market Cap $40.7M
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...

More about SPRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Spero Therapeutics, Inc. Transaction History